Sydnexis receives another regulatory approval for its childhood myopia eye drop; Eli Lilly makes two major investments in ophthalmology; and Nanoscope reports new long-term data for its intravitreal optogenetic therapy for RP.

Learn more about your ad choices. Visit megaphone.fm/adchoices